SIGA Technologies, a commercial-stage pharma company focused on the health security market, today announced receipt of approximately $16 million of international procurement orders for oral TPOXX (tecovirimat) in August and early September, including an approximate $10 million order by the European Commission, through funds from the European Health Emergency Preparedness and Response Authority (HERA) and implemented via rescEU, and approximately $6 million of orders from two countries in the Asia Pacific region, one of which is a new customer.

The order from the European Commission is for emergency short-term stockpiling and/or deployment of oral TPOXX (tecovirimat) in connection with the monkeypox outbreak. In addition to procuring oral TPOXX through the funding of direct purchases, the European Commission is also coordinating country-level procurement through the use of a joint procurement mechanism. SIGA and its international promotion partner, Meridian Medical Technologies, will continue to pursue multiple paths of coordinating European Union health security.

SIGA expects to complete the delivery of these most recent orders in 2022. To date this year, including the recent orders, SIGA has received approximately $76 million of international orders for oral TPOXX (tecovirimat) from twelve international customers. It is expected that at least $65 million of these orders will be delivered in 2022.

With over 64,000 global cases of monkeypox since May 2022, individual countries, as well as pan-international government organisations and non-governmental organisations (NGOs), have become increasingly focused on addressing the monkeypox outbreak,” said Phil Gomez, CEO, SIGA.

He added, “Procurement of TPOXX by the European Commission and by individual countries represent important steps in addressing the near-term risks of the monkeypox outbreak and toward acknowledging and preparing for the longer-term risks posed by the family of orthopox viruses.”